EcoDrugPlus

5-Hydroxytryptamine Receptor 1f

Ensembl ID : ENSDCDG00000000767
Gene Symbol: HTR1F
3 Cross references
139 Possible Orthologues:

5-Hydroxytryptamine Receptor 2a

Ensembl ID : ENSDCDG00000020116
Gene Symbol: HTR2A
3 Cross references
205 Possible Orthologues:

5-Hydroxytryptamine Receptor 2a

Ensembl ID : ENSDCDG00000014780
Gene Symbol: HTR2A
3 Cross references
206 Possible Orthologues:

5-Hydroxytryptamine Receptor 2b

Ensembl ID : ENSDCDG00000035822
Gene Symbol: HTR2B
3 Cross references
204 Possible Orthologues:

5-Hydroxytryptamine Receptor 2c-Like

Ensembl ID : ENSDCDG00000001885
Gene Symbol: LOC114790697
3 Cross references
202 Possible Orthologues:

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSDCDG00000033024
Gene Symbol: HTR3A
3 Cross references
205 Possible Orthologues:

5-Hydroxytryptamine Receptor 3b

Ensembl ID : ENSDCDG00000033021
Gene Symbol: HTR3B
3 Cross references
175 Possible Orthologues:

5-Hydroxytryptamine Receptor 4

Ensembl ID : ENSDCDG00000033559
Gene Symbol: HTR4
3 Cross references
201 Possible Orthologues:

5-Hydroxytryptamine Receptor 5a

Ensembl ID : ENSDCDG00000007852
Gene Symbol: HTR5A
3 Cross references
202 Possible Orthologues:

5-Hydroxytryptamine Receptor 5a-Like

Ensembl ID : ENSDCDG00000002626
Gene Symbol: LOC114788969
3 Cross references
201 Possible Orthologues:

5-Hydroxytryptamine Receptor 5a-Like

Ensembl ID : ENSDCDG00000025687
Gene Symbol: LOC114784222
3 Cross references
201 Possible Orthologues:

5-Hydroxytryptamine Receptor 6

Ensembl ID : ENSDCDG00000011272
Gene Symbol: HTR6
3 Cross references
115 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).